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Abstract To analyze the genes related to the pathophysiology
of sporadic amyotrophic lateral sclerosis (SALS) we performed
gene pro¢ling of SALS spinal cords using molecular indexing
combined with cDNA microarray. Eighty-four fragments were
cloned in the ¢rst screening procedure with molecular indexing.
Subsequent quantitative microarray screening revealed 11 genes
which were di¡erentially expressed in SALS. Real-time RT-
PCR veri¢ed that the expression level of the following six genes
was altered in SALS: dor¢n, metallothionein-3, 30 kDa TATA-
binding protein-associated factor, neugrin, ubiquitin-like protein
5 and macrophage-inhibiting factor-related protein-8. These re-
sults indicated that genes associated with the ubiquitin^protea-
some system, oxidative toxicity, transcription, neuronal di¡er-
entiation and in£ammation might be involved in the path-
ogenesis of SALS.
3 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most
common neurodegenerative disorders, characterized by selec-
tive motor neuron degeneration in the spinal cord, brainstem
and cortex. Approximately 10% of ALS is familial, and 10^
20% of these familial ALS (FALS) cases are caused by mis-
sense mutations in the Cu/Zn superoxide dismutase (SOD1)
gene [1], while others are considered to be sporadic ALS
(SALS). Although the etiology of SALS is not known, a great
number of studies to date have proposed possible mechanisms
of the motor neuron degeneration in SALS. These include
oxidative toxicity, glutamate receptor abnormality, ubiqui-
tin^proteasome dysfunction, in£ammatory and cytokine acti-
vation, dysfunction in neurotrophic factors, damage to mito-
chondria, cytoskeletal abnormalities and activation of the
apoptosis pathway [2,3]. One of the most promising strategies
to identify pathophysiologically related molecules in SALS
would be the comparison of gene expression pro¢les of human
SALS spinal cords with those of normal controls by the gene
expression pro¢ling technique. The spectrum of obtained
genes di¡erentially expressed in SALS tissues from normal
control tissues would largely depend on the screening systems
employed and tissue samples used, particularly in postmortem
tissues. Used for human postmortem samples this approach
could yield not otherwise obtainable information on the mo-
lecular pathophysiology of neuronal degenerations. The only
report of large-scale gene pro¢ling on SALS tissues to date,
using membrane arrays, has documented that genes involved
in oxidative toxicity, neuroin£ammation, apoptosis, and lipid
metabolism were up-regulated in the spinal cords of SALS
patients [4]. We previously used microarray analysis to detect
di¡erentially expressed genes in FALS transgenic mice, show-
ing that in£ammation- and apoptosis-related genes were up-
regulated in G93A-SOD1 transgenic mice [5]. These results
indicated that molecules with similar functions were associ-
ated with the pathogenesis of both SALS and FALS; how-
ever, it is only able to explain the partial pathomechanism for
SALS motor neuron degeneration. To identify genes di¡er-
entially expressed in the SALS spinal cord, particularly novel
or low-abundant genes, we adopted molecular indexing, a
PCR-based screening procedure, for the primary screening
and performed subsequent cDNA microarray analysis.
2. Materials and methods
2.1. Subjects
Postmortem spinal cords samples at segments L3^L5 were taken
from eight SALS patients and eight non-neurological disease controls
after obtaining their informed consent. Each SALS case was clinically
and pathologically veri¢ed. Diagnostic criteria for ALS were based on
the El Escorial criteria outlined by the World Federation of Neurol-
ogy [6]. Bunina body inclusions and hyaline ubiquitinated inclusions
were detected in the residual motor neurons in all SALS cases. One
SALS case (ALS1) and a control (C1) were used for the molecular
indexing. Five cases each (ALS1^5 and C1^5) were analyzed for the
second screening, microarray analysis. For veri¢cation, real-time RT-
PCR with TaqMan probe was performed on all cases (Table 1). Each
autopsy was performed within 9 h post mortem, and spinal cord
samples of lumbar segments (L4/L5) were snap frozen in liquid nitro-
gen, then stored at 380‡C until use. Total RNA was isolated from
anterior horn specimens, where motor neurons exist, using the Micro
RNA Isolation Kit (Stratagene, La Jolla, CA, USA), and it was
reverse transcribed by MMLV reverse transcriptase, Superscript II
(Life Technologies, Grand Island, NY, USA).
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2.2. Molecular indexing and collection of screened cDNAs
SALS (ALS1) and control (C1) spinal cords were used for molec-
ular indexing. Brie£y, after synthesizing from total RNA, double-
stranded cDNA was cut with one of three class IIS restriction en-
zymes, BsmFI, BsmAI or FokI, and ligated to each of 64 biotinylated
adapters cohesive to all possible overhangs. Ligated molecules were
digested by the other class IIS restriction enzymes, and were recovered
with streptavidin-coated paramagnetic beads. PCR was performed
with the adapter primer and an anchored oligo-dT primer. The am-
pli¢ed fragments were separated by polyacrylamide gel electrophore-
sis. By carrying out the experiment with 64 adapters, three enzymes
and three anchored oligo-dT primers, a total of 576 pro¢les of cDNAs
were established. This procedure has been described in detail in pre-
vious reports [7,8].
The 576 pro¢les obtained from the SALS spinal cords were com-
pared with those from the controls, and the cDNA fragments with an
apparent di¡erence in peak between the ALS spinal cord and control
were chosen as candidate gene fragments. The standard used for this
selection was that ratios between SALS and control were more than 5
or less than 0.2. The puri¢ed PCR products were inserted into pGEM
T-Easy vector (Promega). The insert was sequenced using an autose-
quencer. The sequence was applied to the search for the information
using BLAST of NCBI on the web.
2.3. Screening by custom-spotted cDNA microarray
The cDNA fragments obtained were ampli¢ed and spotted on glass
arrays in duplicate (DNA Chip Research, Kanagawa, Japan). The
samples of total RNA (5 Wg) were reverse transcribed into ¢rst-strand
cDNA using 20 U Superscript II and 1 Wl of 0.5 mg/ml T7-oligo-dT
primer (5P-TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG
ACT CAC TAT AGG GCG T21-3P) at 42‡C for 1 h in 20 Wl of
reaction [1U¢rst-strand reaction bu¡er, 10 mM dithiothreitol
(DTT), 0.25 mM dNTPs, 20 U RNasin (Promega, Madison, WI,
USA)]. Next, 30 Wl of 5Usecond-strand synthesis bu¡er, 3 Wl of 10
mM dNTPs, 4 Wl DNA polymerase I, 1 Wl Escherichia coli RNase H,
1 Wl E. coli DNA ligase and 92 Wl of RNase-free H2O were added,
incubated at 16‡C for 2 h, then incubated at 16‡C for 10 min after
the addition of 2 Wl of T4 DNA polymerase. The double-stranded
cDNA was extracted with 150 Wl of phenol^chloroform to eliminate
proteins and then puri¢ed using a Microcon-100 column (Millipore,
Tokyo, Japan) to separate out the unincorporated nucleotides and
salts. RNA ampli¢cation was performed using Ampliscribe T7 Tran-
scription Kit (Epicentre Technologies, Madison, WI, USA) in a mix-
ture of 8 Wl double-stranded cDNA, 2 Wl of 10UAmpliscribe T7 bu¡-
er, 1.5 Wl each of 100 mM ATP, CTP, GTP and UTP, 2 Wl 0.1 M
DTT and 2 Wl of T7 RNA polymerase, which were incubated at 42‡C
for 3 h. The ampli¢ed RNA was puri¢ed with RNeasy Mini Kits
(Qiagen, Valencia, CA, USA). T7 RNA polymerase-ampli¢ed RNA
(aRNA) from control mix and SALS was labeled with Cy3 and Cy5
£uorescence dyes, respectively, using the Atlas Glass Fluorescent La-
beling Kit (Clontech, Palo Alto, CA, USA).
Cy3- and Cy5-labeled probes were hybridized to the custom-spotted
arrays described above at 62‡C for 16 h in a solution of 2UDen-
hardt’s solution, 4USSC and 0.2% SDS. After hybridization the ar-
rays were washed in 2USSC^0.1% SDS and 0.2USSC for 20 min,
respectively, and then rinsed with 0.2USSC and 0.05USSC. The
slides were air-blown dried and prepared for scanning. The micro-
arrays were scanned for £uorescence with GenePix (Axon, Union
City, CA, USA).
2.4. Real-time RT-PCR
First-strand cDNA was synthesized from total RNA (1 Wg) using 20
U Superscript II. Real-time RT-PCR was carried out using iCycler
system (Bio-Rad Laboratories, Hercules, CA, USA) as described else-
where [9]. All experiments were carried out in quadruplicate, and
several negative controls were included. Fluorescence emission spectra
were continuously monitored and analyzed with sequence detection
software. For internal standard control, the expression of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was quanti¢ed simulta-
neously.
Primers and probe sequences (forward primer, reverse primer, and
TaqMan probe): [GAPDH] 5P-CCT GGA GAA ACC TGC CAA
GTA T-3P, 5P-TGA AGT CGC AGG AGA CAA CCT-3P, 5P-CAT
CAA GAA GGT GGT GAA GCA GGC ATC-3P ; [clone 1] 5P-CCG
TCA CTC AAA AGG TTG AA-3P, 5P-TGG CGT GTG AAG TGA
CTT TT-3P, 5P-AGC ATG AAG AGA CCT TTG AGG AGA AAC
TAG TG-3P ; [clone 2] 5P-AAG AGC AAG GAC CGC AAG TA-3P,
5P-GGG TGG CTC AGG TGA AGT AG-3P, 5P-CTC AGC GAG
TAT GGC ATC AAT GTG AAG AAG-3P ; [clone 3] 5P-TAG GAG
CCA TCC GAG ACA AC-3P, 5P-TAC CAT GGC ACT TCC TGA
CA-3P, 5P-CAC TAG CTG GAG CCA GTA TAA CGG GGA-3P ;
[clone 4] 5P-GAA GCT GAA GCA GGA TCA AA-3P, 5P-AGG GAG
CAG CTT TCA CCT AT-3P, 5P-AAG TCC TTA AGA AAG CTG
GGC TTG CCC AC-3P ; [clone 5] 5P-GCC TGT TCT GTC ACC
ATC AA-3P, 5P-GCA GAG GCC ACA GGT TTA GA-3P, 5P-CCA
TTC AGC AGT CCA TTG AAA GGC TCT TAG-3P ; [clone 6] 5P-
CCT GTT GGA GGA GCA GAA CT-3P, 5P-GAA GCC ACA GAC
AGC ACA GA-3P, 5P-AGG GCC CTA ACT ACC TGA CGG CCT
GT-3P ; [clone 7] 5P-GTT GAC CGA GCT GGA GAA AG-3P, 5P-
CCT GTA GAC GGC ATG GAA AT-3P, 5P-CAT CGA CGT CTA
CCA CAA GTA CTC CCT GAT-3P ; [clone 8] 5P-AAG TGC GAG
GGA TGC AAA T-3P, 5P-ACA CAG TCC TTG GCA CAC TT-3P,
5P-ACC TCC TGC AAG AAG AGC TGC TGC TC-3P ; [clone 9] 5P-
TCC CTT GAT CCC ACA AGT TC-3P, 5P-ACA GGC ATA CAC
CAC CAC AT-3P, 5P-AGG CAG CAT AGT GAG ACC CCC ATC
TCT ATA-3P ; [clone 10] 5P-AGC TGC AGA ACA AGG AGC AT-
3P, 5P-GTG AAG CCC CAC TTC TTT GA-3P, 5P-AGT TCA AGT
TTC CTG GCC GCC AGA AGA T-3P ; [clone 11] 5P-ACT GGT
ACC CGT TGG AAC AA-3P, 5P-GTT CAT CCC ATC GTG GAT
TT-3P, 5P-TGG TAC ACG ATT TTT AAG GAC CAC GTG TCT-
3P.
Table 1
Details of patients
Patient Age at death (years) Sex Postmortem interval (hours) Disease duration (months)
ALS1 79 F 6 36
ALS2 67 F 6 48
ALS3 47 F 6 17
ALS4 74 M 6 45
ALS5 65 M 7 56
ALS6 57 M 5 48
ALS7 59 F 3 16
ALS8 57 M 6 68
C1 57 M 2
C2 72 M 4.5
C3 78 M 4.5
C4 52 F 6
C5 75 M 3
C6 65 F 6
C7 48 M 6
C8 42 M 9
ALS Ave. 63.1S 10.3 5.6 S 1.2
Control Ave. 61.1S 13.4 5.1 S 2.2
ALS1^8 are SALS patients. C1^8 are controls without neurological diseases.
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2.5. Statistics
Because of the size and distribution of the samples, a non-para-
metric two-tailed test was chosen (Mann^Whitney U-test). Signi¢cant
values were calculated using StatView software (Hulinks, Tokyo, Ja-
pan).
3. Results and discussion
3.1. Molecular indexing and subsequent cDNA microarray
analysis
Molecular indexing is a modi¢ed version of di¡erential dis-
play. Compared with commercially based cDNA microarrays,
these PCR-based screening procedures have the advantage of
being able to cover an unrestricted range of expressed genes
and to detect mRNAs of low abundance [10]. On the other
hand, only one or a very limited number of samples can be
practicably screened. Compared with conventional di¡erential
displays, this technique displays genes with the least redun-
dancy and is less sensitive to the quality of RNA, which is
advantageous in handling clinical materials [7,8].
The 576 electropherograms obtained from the SALS spinal
cords were compared to control spinal cords. Eighty-four
fragments with obvious di¡erences in intensity were obtained.
Forty-six of the 84 fragments showed stronger expression in
the SALS spinal cord. The other 38 were highly expressed in
the control spinal cord. Among the 84 fragments, 58 matched
known genes in BLAST searches, 17 were expressed sequence
tags (ESTs) and nine matched neither known genes nor ESTs
(Table 2).
For the second screening, we spotted the 84 fragments on
glass arrays and hybridized £uorescent aRNA from the SALS
and control spinal cords (ALS1^5 and C1^5) on the arrays.
The aRNA samples of all the control cases were mixed and
used for the comparison with each SALS case. The expression
ratio was calculated by dividing the £uorescence intensity of
gene elements in each SALS sample by the £uorescence inten-
sity of gene elements in the control mix. Several genes mark-
edly altered their expression levels in the spinal cords between
SALS and control mix (Fig. 1). Genes whose expression was
consistently di¡erent (ratio of more than 2.0 or less than 0.5,
SALS/control) between each SALS case and control mix were
selected as the second candidates. Four genes showed stronger
signals (clones 1^4) and seven showed weaker signals (clones
5^11) in the SALS spinal cords (Table 3).
3.2. Veri¢cation of candidate genes by real-time RT-PCR
The expression of 11 candidate clones in the SALS and the
control spinal cords was examined by real-time RT-PCR us-
ing TaqMan probes. Six clones were determined to have sig-
ni¢cantly di¡erent expression in the SALS spinal cords. Three
clones (2, 3 and 4) were signi¢cantly up-regulated in SALS
cases compared with controls (P6 0.05), and the other three
clones (7, 8 and 11) showed signi¢cantly lower expression in
SALS cases than in controls (P6 0.05). However, clones 1, 5,
6, 9 and 10 showed no signi¢cant di¡erence (Fig. 2).
A similarity search revealed that clones 2, 7, 8 and 11 were
identical to four known cDNAs, 30-kDa TATA-binding pro-
tein-associated factor (TAFII30), macrophage-inhibiting fac-
tor-related protein-8 (MRP8), metallothionein-3 (MT-3) and
ubiquitin-like protein 5 (UBL5), respectively. Clones 3 and 4
proved to be identical to ESTs. We cloned these two unknown
Table 2
Candidate fragments from molecular indexing
Up-regulated in ALS Down-regulated in ALS Total
BLAST matched genes 35 23 58
EST 6 11 17
Genome data base 5 4 9
Total 46 38 84
Molecular indexing yielded 84 candidate genes di¡erentially expressed in SALS spinal cord compared with control spinal cord.
Fig. 1. Close-up image of microarray. Two di¡erent £uorescence
dyes, Cy3 and Cy5, were on the array together. A stronger Cy3 sig-
nal (green) indicates down-regulation and a stronger Cy5 signal
(red) indicates up-regulation in SALS. For example, clone 1 shows
an orange color, implying down-regulation, whereas clone 7 with a
green color is up-regulated in SALS compared to control.
Table 3
Gene expression on microarray analysis
Clone number Expression ratio (ALS/control)
1 2.94S1.33
2 2.67S1.41
3 2.39S1.21
4 2.12S0.77
5 0.44S0.19
6 0.28S0.14
7 0.27S0.21
8 0.36S0.18
9 0.35S0.16
10 0.33S0.15
11 0.45S0.25
Data are meansSS.D. of ¢ve di¡erent SALS case/control mixes.
Genes whose expression was consistently di¡erent (ratio of more
than 2.0 or less than 0.5, SALS/control) between each SALS case
and control mix were selected as the second candidates.
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genes using RACE methods and named them dor¢n and neu-
grin in previous reports [11,12].
TAFII30 is one of the TATA-binding protein-associated
factors required for transcription of a subset of genes [13].
An immunohistochemical study using SCA7 transgenic mice
showed that TAFII30 is accumulated in nuclear inclusions in
neurons. The trapping of this transcription initiation factor in
nuclear inclusions may alter the activity of cellular transcrip-
tion, and contribute to neuronal toxicity in SCA7 model mice
[14]. Our result showed up-regulation of the TAFII30 gene in
the SALS spinal cords, which suggests that this molecule may
also be involved in SALS pathophysiology. More investiga-
tion is necessary to clarify whether up-regulation of this mol-
ecule has a pivotal role in SALS or only re£ects some disrup-
tion of transcription function occurring in SALS.
Dor¢n is a new RING ¢nger-type ubiquitin ligase, contain-
ing two RING ¢nger motifs and an IBR motif at its N-termi-
nus. This gene is ubiquitously expressed in central nervous
system tissues [11]. Our recent study showed that dor¢n is
localized in the ubiquitinated inclusions of FALS and
SALS, bound and ubiquitinated various mutant forms of
SOD1 in vitro, and protected from mutant SOD1-mediated
neurotoxicity in mutant SOD1 culture cells [15]. These results
indicate that dor¢n has a crucial role in the pathomechanism
of mutant SOD1-mediated FALS. In the present study we
showed that the expression of the dor¢n gene was signi¢cantly
higher in the SALS than in the control spinal cords. Consid-
ering that it has a protective function in FALS and is local-
ized in inclusions of SALS, dor¢n may play some protective
role in the pathogenesis of SALS as well. Since some authors
consider that misfolded protein generally play a central role in
various neurodegenerative disorders, such as Huntington dis-
ease, Alzheimer disease, Parkinson disease, familial spinocer-
ebellar degeneration and ALS [16], dor¢n may possibly work
to eliminate proteins which are toxic to motor neurons in the
SALS spinal cord.
The expression of neugrin increases with the process of
neuronal di¡erentiation. This gene is strongly expressed in
the nervous system and mainly in neurons in the spinal cord
[12]. These results indicate that up-regulation of this gene in
the SALS spinal cord re£ects gene expression changes in dying
neurons, not in reactive proliferation of glial cells. However,
the potential role of neugrin remains to be elucidated.
MRP8 is mainly expressed in microglial cells in neuronal
tissues, and it is up-regulated with microglial activation, such
as traumatic injury or viral infection [17,18]. MRP8 decreased
in the SALS spinal cords in the present study. This is para-
doxical because gliosis is one of the hallmarks in ALS path-
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Fig. 2. Veri¢cation of SALS-speci¢c gene expression by real-time RT-PCR. The expression level is shown as the weight ratio of the target gene
to GAPDH. Quanti¢cation of standard templates and each sample was determined by four di¡erent experiments. Eight samples each of SALS
and controls were examined. Values are the meansSS.D., n=8; statistics were carried out by Mann^Whitney U-test. There were signi¢cant dif-
ferences between SALS and control in clones 2, 3, 4, 7, 8 and 11 (P6 0.05). No signi¢cant di¡erence was found for other clones.
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ology. However, it indicates that an in£ammatory disturbance
may in£uence the etiology.
MT-3 is a neuron-speci¢c member of the zinc- and copper-
binding metallothionein family with a role in metal homeo-
stasis and in scavenging free radicals [19,20]. The elevation of
MT-3 expression in G93A SOD1 transgenic mice was re-
ported [21,22], and reduction of MT-3 promotes the onset
of disease and death in G93A SOD1 transgenic mice [23].
In sporadic Alzheimer’s disease brains, MT-3 is signi¢cantly
down-regulated [19,24]. In the present study we demonstrated
that MT-3 mRNA is decreased in the SALS spinal cords, but
another report failed to show a signi¢cant di¡erence in the
MT-3 mRNA expression level in SALS [25]. The fact that
MT-3 was up-regulated in FALS but down-regulated in
SALS leads one to speculate that this molecule may work
for protection in FALS but at the same time may have a
causative role in the disease progression of SALS pathogene-
sis. Although the reduction of its expression might be only
due to the loss of neurons in the SALS spinal cords, we did
not investigate its expression level in single neurons.
UBL5 is one of the ubiquitin-like proteins. It may possibly
organize another ubiquitin-like system, but its function re-
mains unknown [26].
In summary, we identi¢ed six di¡erentially expressed genes
in SALS spinal cords, including two novel genes, using mo-
lecular indexing, subsequent microarray analysis, and real-
time RT-PCR for veri¢cation. These molecules are involved
in cellular mechanisms known to be associated with SALS
pathophysiology, including oxidative toxicity, in£ammation,
transcription and the ubiquitin^proteasome system.
Thus, our screening method using molecular indexing for
preliminary screening was useful to uncover unknown genes
and genes with rather low expression levels that might have
pivotal roles in the pathogenesis of SALS.
Extensive analysis of these genes is necessary to understand
how they participate in the disease course and if they are key
molecules to explore treatments for ALS.
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